AAL

Analyst: This Biopharm Stock Could Barrel Higher

Just two analysts follow Cerecor

Apr 1, 2019 at 11:21 AM
facebook X logo linkedin


Maryland-based orphan disease specialist Cerecor Inc (NASDAQ:CERC) has flown under the radar of analysts. At last Friday's close, just one analyst covered the biopharmaceutical stock, maintaining a "strong buy" rating and $9 price target.

Earlier today, though, H.C. Wainwright initiated coverage on CERC stock with a "buy" rating, and $11 price target -- a more than 88% premium to last week's settlement at $5.84. This follows news from early March that Cerecor and H.C. Wainwright entered into an underwriting agreement.

In reaction, CERC shares are trading up 0.5% at $5.87, extending a recent bounce off its 50-day moving average, and pacing for a third straight win. Longer term, the equity surged 80.8% in the first quarter, marking its best quarter performance since the fourth quarter of 2017, when it gained 276.4%.

Amid this rally, short sellers have been ramping up their exposure. Short interest jumped 33.9% in the two most recent reporting periods. However, the 352,919 Cerecor shares sold short represents just 1.1% of the equity's available float, or 2.3 times the average daily pace of trading.

 

Two High-Octane Trade Ideas. One Simple Goal: Intraday Profits.

Dynamite Day Trading Signals delivers two same-day options trades every week — powered by proprietary intraday analysis and 43+ years of trading expertise.

But this isn’t just another stream of alerts.

It’s a structured plan with clear entry and exit points – designed for traders who want to act fast, trade smart, and wrap up gains before the closing bell.

No guesswork. No overnight exposure – Just two well-researched setups per week — whether you prefer buying premium or selling it.

And the results speak for themselves: subscribers have locked in +245.8% total profit over the last six months (since inception!).

👉 Start your one-month trial now for just $10, and be ready for the next trade alert.